Exenatide (also Exendin-4, marketed as Byetta) is the first of a new class of medications approved for the treatment of type 2 diabetes.
Attributes | Values |
---|---|
rdfs:label |
|
rdfs:comment |
|
sameAs | |
dcterms:subject | |
dbkwik:diabetes/pr...iPageUsesTemplate | |
abstract |
|